吸入不同剂量糖皮质激素治疗咳嗽变异性哮喘的有效性与安全性比较

Efficacy and safety of inhaled different dosage of corticosteroids in the treatment of cough variant asthma

目的比较吸入不同剂量糖皮质激素治疗咳嗽变异性哮喘（CVA）的有效性与安全性。方法选取我院收治的CVA患者120例，将其随机分为三组，各40例。甲、乙、丙三组患者在常规治疗基础上分别日吸布地奈德200、400、600μg进行治疗。比较三组患者临床症状评分及不良反应发生率。结果乙组、丙组临床症状评分、症状消失时间相比，无显著差异（P〉0．05），但均显著低于甲组（P〈0．05）；甲组、乙两组间不良反应发生率比较无显著差异（P〉0．05），但均明显低于丙组（P〈0．05）。结论在咳嗽变异性哮喘治疗中，日吸400μg布地奈德可实现最佳的治疗效果，且安全性较高。

Objective To investigate the efficacy and safety of inhaled different dosage of corticosteroids in the treatment of cough variant asthma （CVA）. Methods A total of 120 cases of CVA patients in our hospital were randomly divided into A, B, C group, with 40 cases in each group. On the basis of routine treatment, patients in A, B, C groups were treated with budesonide of 200, 400, and 600 μg respectively. The clinical symptom score and the incidence of adverse reactions were compared between the three groups. Results There was no significant difference in clinical symptom score and the time of disappearance of clinical symptoms between group B and group C （P〉0.05）, but the clinical symptom score and the time of disappearance of clinical symptoms of group B and C were significantly better than those of the group A （P〈0.05）; there was no significant difference in the incidence of adverse reactions between group A and group B （P〉0.05）, but the incidences of adverse reactions of group A and group B were significantly lower than that of group C （P〈0.05）. Conclusion In the treatment of cough variant asthma, daily inhalation of 400 μg hudesonide can achieve the best treatment effect, and has high safety.